Skip to content
Biomeme Labs
Labs

One sample shows where you stand. A series shows what moves.

Your first sample starts your personal baseline. After that, samples timed around changes in your therapy show which readings moved and by how much. This is a suggested cadence; you and your clinician can set your own.

Four suggested samples,
timed around changes in your therapy.

Give samples at these points, add some in between, or set your own cadence. Two samples make a comparison, and three or more begin a trend. Your report names the window for your next sample.

Day 0

Your first sample starts your baseline

Before your first dose, or whenever you begin. Your Bearing shows where each of your six readings sits against the reference group, people whose blood was measured the same way: within its reference range, at its edge, below it or above it. You also see your immune cell mix. Your Course and Your Map fill in from your second sample.

Week 4

Early in dose increases

In SELECT, hs-CRP fell by weeks 4 and 8, before major weight loss, and fell even in participants who did not lose weight.6 A sample here shows which of your readings moved since your baseline and which stayed about the same, whatever the scale is doing.

Week 12

Around a maintenance dose

A third sample is where a trend begins, so you can start to tell a passing shift from a pattern. It can be useful during a weight plateau, when the scale and routine labs hold steady: your clinician sees which readings moved in the same period.

Month 12+

Maintenance, a dose change or a stop

Yearly, or around any change your prescriber makes. Your Map plots your Activation Level and Resolution Level from every sample, so the path you’ve taken runs across the page, with the reference group drawn around it as the galaxy.

Before and after a taper

Results are expected about one month after laboratory receipt. We’ll email you when your report is ready to download as a PDF from your dashboard.

Already on a GLP-1?
It isn't too late.

Your first sample becomes your baseline from that point on. It can’t show what changed before you gave it, so it won’t tell you what the medication has already done. It will show where you stand now, and later samples will show what moves from here, including after a dose change, a pause or a taper.

The off-ramp is a bigger moment
than the on-ramp.

In a cohort of 125,474 adults with overweight or obesity, 64.8% of those without type 2 diabetes stopped GLP-1 therapy within 12 months,1 and commercial claims data found three-year persistence among members without diabetes of about 8%.2

In the STEP 1 extension, participants regained two-thirds of lost weight within a year of stopping semaglutide; CRP rose partway back but stayed below baseline.3 In SURMOUNT-4, participants switched to placebo regained 14.0% of body weight over 52 weeks.4 Research on weight loss after surgery and diet found that fat tissue retains a memory of obesity; whether the same happens after GLP-1 withdrawal has not been tested.5

2–4 weeks before

A sample at maintenance

Before a clinician-guided dose reduction or longer spacing, a sample records your six readings and immune cell mix on a steady dose, so later samples have a point of comparison.

3–6 months after

A sample after the taper or stop

Your Course shows which readings moved since the maintenance sample and which stayed about the same, to read with your clinician beside your weight and routine labs.

Your inflammation shifts a little every day.
A reading is marked as moved only when the shift is bigger.

Gene activity moves from day to day with sleep, exercise, stress, illness and the time of day. So the report marks a reading as moved only when the shift is larger than the usual difference between two samples taken close together. Anything smaller is marked about the same.

The more samples behind a pattern, the more weight it can carry. Giving each sample under similar conditions makes them easier to compare.

What it
can't tell you.

The Inflammation Compass shows what changed and by how much. It can’t show why, because many things move these readings, and it doesn’t show whether a medication is working or is safe. It doesn’t diagnose, rule out or predict any disease.

Dose changes, tapers and decisions to stop stay with your prescriber. What a change means is for you and your clinician to weigh.

Plan your baseline and the samples after it.

Reserve your spot and share your testing preferences.

$389 per test, or $365 each when you order 4 or more. Mobile phlebotomy and shipping included.

Sources and further reading

Clinical evidence & references

1. Rodriguez PJ, et al. (2025) — Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 8(1):e2457349. doi:10.1001/jamanetworkopen.2024.57349. PMID 39888616.
2. Prime Therapeutics (2025) — GLP-1 therapy to treat obesity among members without diabetes: three-year persistence. Real-world commercial claims analysis. June 2025.
3. Wilding JPH, et al. (2022) — Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 24(8):1553–1564. doi:10.1111/dom.14725. PMID 35441470.
4. Aronne LJ, et al. (2024) — Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 331(1):38–48. doi:10.1001/jama.2023.24945. PMID 38078870.
5. Hinte LC, et al. (2024) — Adipose tissue retains an epigenetic memory of obesity after weight loss. Nature. 636:457–465. doi:10.1038/s41586-024-08165-7. PMID 39558077.
6. Plutzky J, et al. (2026) — Effect of semaglutide on the inflammatory biomarker high-sensitivity CRP in patients with established cardiovascular disease and overweight or obesity in SELECT: a prespecified secondary analysis. Circulation. 154(11):976–991. doi:10.1161/CIRCULATIONAHA.125.074482. PMID 42610271.